4,784 results on '"Saab AS"'
Search Results
2. Polynomial Time Cryptanalytic Extraction of Neural Network Models
3. TERAPÊUTICAS AVANÇADAS E CONTROLE DE COMPLICAÇÕES PRECOCES E TARDIAS EM PROCEDIMENTOS ENDOSCÓPICOS (SANGRAMENTO E PERFURAÇÕES)
4. Mobile Kasambahay
5. L’État dans tous ses états : Quelques réflexions sur les récents repli puis rebonds du rôle de l’État en société et au plan international
6. Digital Citizenship and Digital Literacy
7. Developing a Comprehensive Search Strategy for the Systematic Review of Clinical Decision Support Systems for Nursing Practice
8. The Impact of Artificial Intelligence on Search Engine
9. Arterial Revascularization
10. Contributors
11. Zu nah dran und gerade deshalb gut? Die Rolle von Aussteiger:innen in der Deradikalisierungs- und Distanzierungsarbeit
12. South-American Languages in a Formal Perspective
13. Fault Detection in Induction Machines of Air Handling Units
14. The use of biocatalysis for biosurfactant production
15. Characterization of Isoclinic, Transversally Geodesic and Grassmannizable Webs
16. Enfortumab Vedotin Drug Eruption: Cutaneous Adverse Events and Histopathologic Findings
17. Supplementary Table S2 from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
18. Supplementary Figure S1 from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
19. Supplementary Table S1 from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
20. Supplementary Figure S1 from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
21. Supplementary Table S5 from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
22. Supplementary Figure S2 from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
23. Supplementary Figure S2 from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
24. Supplementary Appendix from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
25. Supplementary Table S4 from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
26. Data from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
27. Supplementary Table S5 from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
28. Supplementary Table S1 from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
29. Supplementary Table S3 from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
30. Supplementary Table S3 from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
31. Supplementary Table S4 from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
32. Supplementary Table S2 from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
33. Supplementary Appendix from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
34. Supplementary Appendix from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
35. Supplementary Table S3 from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
36. Supplementary Table S2 from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
37. Supplementary Appendix from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
38. Supplementary Table S4 from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
39. Supplementary Figure S2 from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
40. Supplementary Table S1 from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
41. Data from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
42. Supplementary Table S1 from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
43. Supplementary Table S5 from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
44. Supplementary Figure S1 from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
45. Supplementary Figure S2 from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
46. Supplementary Table S2 from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
47. Supplementary Table S4 from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
48. Supplementary Table S5 from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
49. Supplementary Table S3 from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
50. Supplementary Figure S1 from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.